Clinical Edge Journal Scan

Cannabis use is more prevalent in patients with atopic dermatitis


 

Key clinical point : The likelihood of using cannabis was significantly higher, whereas that of using e-cigarettes and regular cigarettes was significantly lower, in patients with atopic dermatitis (AD).

Major finding: Patients with AD vs control individuals without AD were significantly more likely to use cannabis (adjusted odds ratio [aOR] 1.49; P < .01) but less likely to use e-cigarettes (aOR 0.71; P < .01) and regular cigarettes (aOR 0.65; P < .01). No significant association was observed between AD and hallucinogen ( P = .60), opioid ( P = .07), and stimulant ( P = .20) use.

Study details: This nested case-control study included 13,756 patients with AD and 55,024 age-, race/ethnicity-, and sex-matched control individuals without AD.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Joshi TP et al. Association of atopic dermatitis with substance use disorders: A case-control study in the All of Us Research Program. J Am Acad Dermatol. 2023 (Jul 13). doi: 10.1016/j.jaad.2023.06.051

Recommended Reading

History of herpes zoster predicts recurrence during treatment of atopic dermatitis with upadacitinib
MDedge Dermatology
Probiotic intake by breastfeeding mothers halves the incidence of atopic dermatitis in children
MDedge Dermatology
Sibship composition and size alter the risk for atopic dermatitis
MDedge Dermatology
Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023
MDedge Dermatology
Free teledermatology clinic helps underserved patients initiate AD care
MDedge Dermatology
Economic Burden and Quality of Life of Patients With Moderate to Severe Atopic Dermatitis in a Tertiary Care Hospital in Helsinki, Finland: A Survey-Based Study
MDedge Dermatology
Nemolizumab shows promise in pediatric atopic dermatitis with inadequately controlled pruritus
MDedge Dermatology
Amlitelimab is effective and well-tolerated in atopic dermatitis inadequately controlled by topical therapies
MDedge Dermatology
Continuous upadacitinib treatment required to maintain skin clearance in atopic dermatitis
MDedge Dermatology
Abrocitinib is safe and effective against difficult-to-treat atopic dermatitis in daily practice
MDedge Dermatology